A historical TR-beta probe now outclassed by resmetirom; retains niche value in RTH syndrome research
Look, TRIAC is one of those compounds that used to be the most interesting thing in its zip code and simply isn’t anymore. It’s a natural T3 metabolite, formed by deamination and oxidative decarboxylation of T3, and it retains thyroid receptor activity with a modest TR-beta preference somewhere around 2 to 4-fold over TR-alpha. That selectivity ratio was genuinely exciting in the 1980s and early 1990s when TR-beta-selective thyromimetics were a hot theoretical concept. It’s a lot less exciting now that resmetirom (Rezdiffra) has been FDA-approved for MASH with a vastly superior selectivity profile and a phase 3 dataset behind it.
The TR-beta biology here is real. TR-beta drives effects in the pituitary and liver; TR-alpha drives the cardiac and skeletal effects you don’t want. TRIAC’s selectivity is enough to produce the pituitary suppression you need in resistance to thyroid hormone syndrome (Refetoff syndrome) without the same degree of tachycardia and bone turnover you’d get from equivalent T3 exposure. That’s why it’s approved in France, Mexico, and a handful of other markets for RTH. It’s a legitimate approved compound with a real mechanism solving a real problem in a real patient population. We don’t want to dismiss that.
What we do want to flag is that the population is rare, the clinical trials were small, and the broader thyromimetic literature has moved decisively past TRIAC in terms of selectivity and precision. Sobetirome, VK2809, and now resmetirom all do the TR-beta job better. The fat loss angle, which drove a lot of the underground use, produced enough serious thyrotoxic events at supratherapeutic doses to prompt FDA enforcement actions against supplement products containing it. Thats not a research dead end exactly, but it is a credibility problem for any investigator trying to study TRIAC as a metabolic tool in 2025.
Where TRIAC still earns its place in a serious research library is as a reference thyromimetic. If you’re doing TR-beta selectivity work, you need a physiologically relevant natural metabolite as your comparator. TRIAC fills that role. It has decades of receptor-binding data, a well-characterized PK profile (roughly 7-hour half-life, shorter than T4, longer than T3), and the kind of historical dataset that lets you anchor new results against a known standard. The bench utility is real but bounded. You’re reaching for TRIAC when you need that physiological reference, not when you’re trying to advance the field.
Honestly, the score of 41 reflects exactly this situation: a compound that mattered, still has a defined niche, but isn’t where a serious investigator puts their next research dollar unless RTH syndrome or TR-beta reference biology is the specific program. Good tool. Not a frontier compound.